Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123

• Status: Completed
• Trial end date: 2019-09-20
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to find out if the small dose of radioiodine, that is used for the dosimetry study on patients with differentiated thyroid cancer, may stun the cancer cells and make the thyroid cancer treatment less effective.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver

Criteria

Inclusion Criteria:

• Patient must be 21-years-old or greater.

• Patient must be status post near total thyroidectomy for differentiated thyroid cancer without known distant metastases and who are planning to undergo routine remnant thyroid tissue ablation with I-131.

• Patients must qualify for thyroid ablation with I-131.

Exclusion Criteria:

• Women who are pregnant or breastfeeding.

• Prior bovine TSH use.

• Known metastatic thyroid cancer.

• History of cardiovascular disease that may adversely affect patient participation at the discretion of the primary investigator.

• Patients on hemodialysis.

• Patients with acute serious illnesses at the discretion of the primary investigator.